BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2009527)

  • 1. Mathematical model of granulocytopoiesis and chronic myelogenous leukemia.
    Fokas AS; Keller JB; Clarkson BD
    Cancer Res; 1991 Apr; 51(8):2084-91. PubMed ID: 2009527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mathematical modeling of genesis and treatment of chronic myeloid leukemia.
    Horn M; Loeffler M; Roeder I
    Cells Tissues Organs; 2008; 188(1-2):236-47. PubMed ID: 18303243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X; Saw KM; Eaves A; Eaves C
    J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The allometry of chronic myeloid leukemia.
    Pacheco JM; Traulsen A; Dingli D
    J Theor Biol; 2009 Aug; 259(3):635-40. PubMed ID: 19362566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human stem cell model to study signal transduction and molecular regulation mechanisms in CML.
    Fan E; Hu Y; Zhao C
    Chin Med J (Engl); 2001 Jul; 114(7):680-4. PubMed ID: 11780326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
    Schultheis B; Pasternak G; Hehlmann R
    Folia Biol (Praha); 2000; 46(6):256-63. PubMed ID: 11140859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction.
    Moore H; Li NK
    J Theor Biol; 2004 Apr; 227(4):513-23. PubMed ID: 15038986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retroviral transduction of Philadelphia-positive chronic myeloid leukemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation.
    Bi S; Barton CM; Lemoine NR; Cross NC; Goldman JM
    Exp Hematol; 1994 Jan; 22(1):95-9. PubMed ID: 8282066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A PDE model for imatinib-treated chronic myelogenous leukemia.
    Kim PS; Lee PP; Levy D
    Bull Math Biol; 2008 Oct; 70(7):1994-2016. PubMed ID: 18663536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential manipulation of normal and chronic myeloid leukemia stem cell proliferation in vitro.
    Eaves C; Eaves A
    Blood Cells; 1994; 20(1):83-93; discussion 93-5. PubMed ID: 7994064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.
    Ren R
    Oncogene; 2002 Dec; 21(56):8629-42. PubMed ID: 12476309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse in chronic myeloid leukemia after bone marrow transplantation: biomathematical modeling as a new approach to understanding pathogenesis.
    Vincent PC; Rutzen-Loesevitz L; Tibken B; Heinze B; Hofer EP; Fliedner TM
    Stem Cells; 1999; 17(1):9-17. PubMed ID: 10215403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mathematical model of hematopoiesis--I. Periodic chronic myelogenous leukemia.
    Colijn C; Mackey MC
    J Theor Biol; 2005 Nov; 237(2):117-32. PubMed ID: 15975596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
    Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
    Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model mice for BCR/ABL-positive leukemias.
    Honda H; Hirai H
    Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia.
    Lee J; Kim Y; Lim J; Kim M; Han K
    Ann Clin Lab Sci; 2008; 38(4):331-7. PubMed ID: 18988925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia.
    Pierce A; Owen-Lynch PJ; Spooncer E; Dexter TM; Whetton AD
    Oncogene; 1998 Aug; 17(5):667-72. PubMed ID: 9704934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.